Vistagen to Participate in Stifel 2025 Virtual CNS Forum
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and nose-to-brain neurocircuitry, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum. The company's President and CEO, Shawn Singh, will engage in a fireside chat presentation on March 18, 2025, at 12 p.m. Eastern Time.
The company specializes in developing and commercializing a novel class of intranasal product candidates called pherines. Interested parties can access the live webcast through the 'Events' page in the 'Investors' section of Vistagen's website, with a replay available after the event.
Vistagen (Nasdaq: VTGN), un'azienda biofarmaceutica in fase clinica focalizzata sulle neuroscienze e sulla neurocircuiteria naso-cerebrale, ha annunciato la sua partecipazione al prossimo Stifel 2025 Virtual CNS Forum. Il presidente e CEO dell'azienda, Shawn Singh, parteciperà a una presentazione in forma di chiacchierata intima il 18 marzo 2025, alle 12:00 ora orientale.
L'azienda si specializza nello sviluppo e nella commercializzazione di una nuova classe di candidati prodotti intranasali chiamati feromoni. Le parti interessate possono accedere alla diretta web attraverso la pagina 'Eventi' nella sezione 'Investitori' del sito web di Vistagen, con una registrazione disponibile dopo l'evento.
Vistagen (Nasdaq: VTGN), una empresa biofarmacéutica en etapa clínica centrada en la neurociencia y la neurocircuitería nariz-cerebro, ha anunciado su participación en el próximo Stifel 2025 Virtual CNS Forum. El presidente y CEO de la empresa, Shawn Singh, participará en una presentación de charla informal el 18 de marzo de 2025, a las 12 p.m. hora del Este.
La empresa se especializa en el desarrollo y comercialización de una nueva clase de candidatos a productos intranasales llamados feromonas. Las partes interesadas pueden acceder a la transmisión en vivo a través de la página de 'Eventos' en la sección de 'Inversores' del sitio web de Vistagen, con una repetición disponible después del evento.
비스타젠 (Nasdaq: VTGN)은 신경과학 및 비강-뇌 신경회로에 중점을 둔 임상 단계의 생물 제약 회사로, 다가오는 Stifel 2025 가상 CNS 포럼에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 Shawn Singh은 2025년 3월 18일, 동부 표준시 기준 오후 12시에 대화형 발표에 참여할 예정입니다.
회사는 페리네라고 불리는 새로운 종류의 비강 제품 후보를 개발하고 상용화하는 데 전문화되어 있습니다. 관심 있는 분들은 Vistagen 웹사이트의 '투자자' 섹션에 있는 '이벤트' 페이지를 통해 생중계에 접속할 수 있으며, 이벤트 후에는 재방송도 제공됩니다.
Vistagen (Nasdaq: VTGN), une entreprise biopharmaceutique en phase clinique axée sur les neurosciences et la neurocircuiterie nez-cerveau, a annoncé sa participation au prochain Stifel 2025 Virtual CNS Forum. Le président et PDG de l'entreprise, Shawn Singh, participera à une présentation sous forme de discussion informelle le 18 mars 2025 à 12h00, heure de l'Est.
L'entreprise se spécialise dans le développement et la commercialisation d'une nouvelle classe de candidats produits intranasaux appelés phérines. Les parties intéressées peuvent accéder à la diffusion en direct via la page 'Événements' dans la section 'Investisseurs' du site Web de Vistagen, avec une rediffusion disponible après l'événement.
Vistagen (Nasdaq: VTGN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Neurowissenschaften und die Nase-zum-Gehirn-Neurozircuitry konzentriert, hat seine Teilnahme am kommenden Stifel 2025 Virtual CNS Forum angekündigt. Der Präsident und CEO des Unternehmens, Shawn Singh, wird am 18. März 2025 um 12 Uhr Eastern Time an einer informellen Gesprächsrunde teilnehmen.
Das Unternehmen spezialisiert sich auf die Entwicklung und Vermarktung einer neuartigen Klasse von intranasalen Produktkandidaten, die Pherine genannt werden. Interessierte Parteien können über die 'Events'-Seite im 'Investoren'-Bereich der Vistagen-Website auf den Live-Stream zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
Vistagen’s President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m. Eastern Time. A live webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com. A replay of the webcast will be archived and available following the event.
About Vistagen
Headquartered in
Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, which activate olfactory bulb-to-brain neurocircuits without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits and differentiated safety. Vistagen’s neuroscience pipeline also includes an oral prodrug with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304062510/en/
Investor Inquiries:
Mark A. McPartland
markmcp@vistagen.com
Media Inquiries:
Michelle P.
mwellington@vistagen.com
Source: Vistagen
FAQ
When is Vistagen (VTGN) presenting at the Stifel 2025 Virtual CNS Forum?
What type of products is Vistagen (VTGN) developing?
How can investors watch Vistagen's (VTGN) presentation at the Stifel CNS Forum?
What is the format of Vistagen's (VTGN) presentation at the Stifel 2025 Forum?
